Overview

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Status:
Not yet recruiting
Trial end date:
2027-01-29
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche